Albemarle (NYSE:ALB – Get Free Report) was downgraded by stock analysts at Citigroup to a “neutral” rating in a report issued on Friday, Stock Target Advisor reports. They currently have a $120.00 price target on the specialty chemicals company’s stock, down from their previous price target of $175.00. Citigroup’s price objective would indicate a potential upside of 4.96% from the company’s previous close.
Other equities analysts have also issued reports about the stock. KeyCorp reduced their price target on shares of Albemarle from $200.00 to $199.00 and set an “overweight” rating for the company in a research report on Tuesday, January 9th. UBS Group cut their target price on shares of Albemarle from $142.00 to $137.00 and set a “neutral” rating for the company in a report on Tuesday, January 30th. TheStreet lowered shares of Albemarle from a “b-” rating to a “c+” rating in a report on Monday, November 6th. Mizuho cut their target price on shares of Albemarle from $152.00 to $130.00 and set a “neutral” rating for the company in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada cut their target price on shares of Albemarle from $212.00 to $163.00 and set an “outperform” rating for the company in a report on Monday, November 6th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Albemarle has an average rating of “Hold” and an average price target of $200.16.
Albemarle Stock Performance
Institutional Investors Weigh In On Albemarle
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. acquired a new stake in Albemarle during the 3rd quarter worth $25,000. USCF Advisers LLC raised its holdings in shares of Albemarle by 100.0% during the 4th quarter. USCF Advisers LLC now owns 200 shares of the specialty chemicals company’s stock worth $29,000 after acquiring an additional 100 shares during the period. Covestor Ltd raised its holdings in shares of Albemarle by 51.2% during the 1st quarter. Covestor Ltd now owns 130 shares of the specialty chemicals company’s stock worth $29,000 after acquiring an additional 44 shares during the period. Arlington Trust Co LLC purchased a new position in shares of Albemarle during the 4th quarter worth $30,000. Finally, PrairieView Partners LLC raised its holdings in shares of Albemarle by 15,300.0% during the 2nd quarter. PrairieView Partners LLC now owns 154 shares of the specialty chemicals company’s stock worth $34,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 84.71% of the company’s stock.
Albemarle Company Profile
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets.
- Five stocks we like better than Albemarle
- How to Find Cloud Software Company Stocks to Trade and Invest
- New York Community Bank stock plummets amid real estate risks
- How to Invest in Blue Chip Stocks
- The 5 best small cap AI companies to buy now
- Why Consider Investing in Nanotechnology Stocks
- Cirrus Logic: A chip stock you’re going to hear a lot more about
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.